版本:
中国

BRIEF-Acorda qtrly GAAP net loss $0.41 per diluted share

April 27 Acorda Therapeutics Inc:

* Acorda provides financial and pipeline update for first quarter 2017

* Acorda Therapeutics Inc- projected year-end cash balance greater than $200 million

* Acorda Therapeutics Inc- 2017 combined research and development and SG&A operating expense guidance revised to $330 - $350 million, a reduction of about $50 million

* Acorda Therapeutics Inc - qtrly GAAP net loss for quarter ended March 31, 2017, $0.41 per diluted share

* Acorda Therapeutics Inc - qtrly non-gaap net loss for quarter ended march 31, 2017 $.08 per diluted share

* Q1 earnings per share view $0.09, revenue view $127.3 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐